WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD 75.10
+0.60 (0.81%)
Sep 29, 2025, 4:08 PM HKT
WuXi XDC Cayman Revenue
WuXi XDC Cayman had revenue of 2.70B CNY in the half year ending June 30, 2025, with 171.86% growth. This brings the company's revenue in the last twelve months to 5.09B, up 82.00% year-over-year. In the year 2024, WuXi XDC Cayman had annual revenue of 4.05B with 90.80% growth.
Revenue (ttm)
5.09B CNY
Revenue Growth
+82.00%
P/S Ratio
16.54
Revenue / Employee
2.49M CNY
Employees
2,041
Market Cap
92.21B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.05B | 1.93B | 90.80% |
| Dec 31, 2023 | 2.12B | 1.13B | 114.44% |
| Dec 31, 2022 | 990.42M | 679.29M | 218.33% |
| Dec 31, 2021 | 311.13M | 214.78M | 222.91% |
| Dec 31, 2020 | 96.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |